Recombinant erythropoietin is a form of erythropoietin that is produced through DNA recombinant technology and not extracted from urine. It is used mainly to treat anemia associated with chronic kidney disease and HIV/AIDS. It stimulates red blood cell production and helps avoid regular blood transfusions. The recombinant form is widely used due to its higher effectiveness and purity compared to urinary erythropoietin.
The primary drivers expected to boost growth of the recombinant erythropoietin market include rising incidence of cancer and CKD across the globe. According to the National Cancer Institute, in 2023 around 1.9 million new cancer cases are likely to be diagnosed in the U.S. Further, as per the WHO, globally about 1.1 billion people suffer from some type of chronic kidney disease and the condition is rising rapidly. Another major driver is the approval of new indications of recombinant erythropoietin such as its use in chemotherapy-induced anemia and pre-operative blood transfusion optimization. However, risks associated with recombinant erythropoietin treatment such as thrombosis acts as a challenge for market growth. Nevertheless, continuous development of technologically advanced versions of erythropoiesis-stimulating agents is expected to offer substantial growth opportunities over the forecast period.
The global Recombinant Erythropoietin Market Share is estimated to be valued at US$ 7.01 Billion in 2023 and is expected to exhibit a CAGR of 2.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
The recombinant erythropoietin market is segmented into epoetin alfa, epoetin beta, darbepoetin alfa and others. Among these, epoetin alfa dominates the market with over 50% share as it is the first erythropoietin drug launched in the market and is approved for a wide range of therapeutic applications such as chemotherapy-induced anemia and chronic kidney disease.
Political: Government regulations around the pricing of biologics impact the market. Economic: Rising prevalence of chronic kidney disease and cancer are driving demand. Social: Growing awareness about available treatment options and supportive reimbursement policies foster adoption. Technological: Scientists are developing novel erythropoietin molecules with improved efficacy and safety profiles.
The global recombinant erythropoietin market is expected to witness high growth, exhibiting CAGR of 2.0% over the forecast period, due to increasing prevalence of kidney ailments and growing cancer caseload worldwide. Regionally, North America commands the largest share mainly because of rising incidence of chronic kidney disease in the US and Canada. Europe holds the second largest share owing to increasing healthcare expenditures.
The recombinant erythropoietin market size for 2023 is estimated at US$ 7.01 Bn.
Key players operating in the recombinant erythropoietin market are Amgen Inc., Johnson & Johnson (Janssen Pharmaceuticals), Pfizer Inc., Roche Holding AG, Novartis AG, Biocon Limited, Teva Pharmaceutical Industries Ltd., LG Chem Ltd., Sandoz International GmbH (a subsidiary of Novartis AG), Intas Pharmaceuticals Ltd., Dr. Reddy’s Laboratories Ltd., Celltrion Inc., 3SBio Inc. and CJ CheilJedang Corporation. Recombinant erythropoietin has revolutionized anemia management, significantly improving quality of life for millions of patients worldwide. Key players are focused on expanding their product portfolios and strengthening global distribution networks.
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it